Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Breast Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 43 articles: HTML format

Single Articles

October 2026
1. XIA L, Gong Y, He C, Mei B, et al
   B7H3-Targeted Molecular Imaging for Highly Specific Diagnosis and In Vivo Noninvasive Detection of B7H3 in Breast Cancer.
   J Nucl Med. 2026 Oct 15:jnumed.126.272939. doi: 10.2967/jnumed.126.272939.
   PubMed     Abstract available
   
   
   
2. GE S, Li J, Shi J, Jia T, et al
   (68)Ga-Labeled Dimeric Cyclic Peptide for Nectin-4-Targeted PET Imaging: From Preclinical Evaluation to First-in-Human Imaging in Breast Cancer.
   J Nucl Med. 2026 Oct 8:jnumed.126.273306. doi: 10.2967/jnumed.126.273306.
   PubMed     Abstract available
   
   
   September 2026
3. NDLOVU H, Lawal IO, Moholisa RR, Kabunda J, et al
   Lesion Detection and Uptake Patterns of [(18)F]F-ATD001 PET/CT and [(18)F]FDG PET/CT in Triple-Negative Breast Cancer.
   J Nucl Med. 2026 Sep 10:jnumed.125.271973. doi: 10.2967/jnumed.125.271973.
   PubMed     Abstract available
   
   
   August 2026
4. GAO S, Zhang Z, Shi C, Cheng C, et al
   (68)Ga-HER2 PET/CT for Predicting Pathologic Response to Neoadjuvant Therapy at Early Treatment and Preoperative Stages in HER2-Positive Breast Cancer: A Prospective Study.
   J Nucl Med. 2026 Aug 6:jnumed.125.271529. doi: 10.2967/jnumed.125.271529.
   PubMed     Abstract available
   
   
   June 2026
5. KUPER AT, Shiyam Sundar LK, Djaileb L, Roschlak J, et al
   SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [(68)Ga]Ga-DOTATOC and [(68)Ga]Ga-SSO120 with [(18)F]FDG PET.
   J Nucl Med. 2026 Jun 25:jnumed.126.272521. doi: 10.2967/jnumed.126.272521.
   PubMed     Abstract available
   
   
   May 2026
6. DUIJX LEHW, Lenaerts M, Smidt ML, Vaz SC, et al
   Diagnostic Performance of FAPI PET in Patients with Breast Cancer: A Systematic Review.
   J Nucl Med. 2026 May 14:jnumed.126.272191. doi: 10.2967/jnumed.126.272191.
   PubMed     Abstract available
   
   
   
7. JIA W, Yan T, An S, Zhang Y, et al
   Immuno-PET/CT Imaging of Trop2 Expression with [(18)F]AlF-RESCA-RT4 Enhances Diagnosis of Breast Cancers and the Metastases.
   J Nucl Med. 2026 May 14:jnumed.125.271093. doi: 10.2967/jnumed.125.271093.
   PubMed     Abstract available
   
   
   February 2026
8. COLD S, Sadasivam P, Wessel MM, Ischyropoulou M, et al
   In Vivo Studies of [(161)Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2-Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression.
   J Nucl Med. 2026 Feb 12:jnumed.125.269741. doi: 10.2967/jnumed.125.269741.
   PubMed     Abstract available
   
   
   January 2026
9. NIJVELDT JJ, Af Buren S, Tran TA, Jussing E, et al
   Feasibility of [(89)Zr]Zr-Atezolizumab Immuno-PET for PD-L1 Quantification in the Clinical Work-up of Metastatic Triple-Negative Breast Cancer.
   J Nucl Med. 2026 Jan 29:jnumed.125.271459. doi: 10.2967/jnumed.125.271459.
   PubMed     Abstract available
   
   
   
10. AKCA U, Song PN, Devalankar D, Yasui N, et al
    Preclinical Comparison of (18)F-Labeled Amino Acids Targeting Different Transporter Systems for PET Imaging of Triple-Negative Breast Cancer.
    J Nucl Med. 2026 Jan 8:jnumed.125.270225. doi: 10.2967/jnumed.125.270225.
    PubMed     Abstract available
    
    
    December 2025
11. YEH R
    Reply: The Role of HER2 PET in Treatment of Breast Cancer.
    J Nucl Med. 2025 Dec 11:jnumed.125.271241. doi: 10.2967/jnumed.125.271241.
    PubMed    
    
    
    
12. SONG J, Ye J
    Critical Evaluation of HER2 PET Imaging in Metastatic Breast Cancer: Addressing Key Challenges and Future Directions.
    J Nucl Med. 2025 Dec 11:jnumed.125.271101. doi: 10.2967/jnumed.125.271101.
    PubMed    
    
    
    
13. BADING JR, Mortimer JE
    The Role of HER2 PET in Treatment of Breast Cancer.
    J Nucl Med. 2025 Dec 11:jnumed.125.271364. doi: 10.2967/jnumed.125.271364.
    PubMed    
    
    
    
14. SPECHT JM, van Geel JJL, Song S, Liu C, et al
    The Role of Estrogen Receptor-Targeted PET with 16alpha-(18)F-Fluoro-17beta-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis.
    J Nucl Med. 2025 Dec 4:jnumed.125.270763. doi: 10.2967/jnumed.125.270763.
    PubMed     Abstract available
    
    
    October 2025
15. MCNALLY LR, Claros-Sorto JC, Bynum RC, Grizzle WE, et al
    Assessment of Breast Tumors Using Multispectral Optoacoustic Tomography in a Surgical Setting.
    J Nucl Med. 2025;66:1597-1604.
    PubMed     Abstract available
    
    
    
16. KUJAWSKI M, Aniogo E, Wong P, Hui S, et al
    Combination Image-Guided and Antibody-Targeted alpha-Therapy Before Targeted Immunotherapy for Treatment of Solid Tumors.
    J Nucl Med. 2025;66:1605-1611.
    PubMed     Abstract available
    
    
    August 2025
17. RYU J, Han S, Yoo TR, Lee SB, et al
    Diagnostic Performance of (18)F-Fluoroestradiol PET/CT for Axillary Lymph Node Metastasis in Invasive Lobular Carcinoma: A Prospective Feasibility Study.
    J Nucl Med. 2025 Aug 14:jnumed.125.269573. doi: 10.2967/jnumed.125.269573.
    PubMed     Abstract available
    
    
    
18. HUANG W, Li L, Chao F, Yang Q, et al
    [(64)Cu]Cu-NOTA-EV-F(ab')(2) Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers.
    J Nucl Med. 2025 Aug 7:jnumed.125.270132. doi: 10.2967/jnumed.125.270132.
    PubMed     Abstract available
    
    
    
19. ENKE JS, Schuller BW, Glantschnig L, Kircher M, et al
    Biodistribution and Radiation Dosimetry for [(68)Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein alpha.
    J Nucl Med. 2025;66:1284-1290.
    PubMed     Abstract available
    
    
    June 2025
20. RINNE SS, Vargas DB, Seo S, Veach D, et al
    (225)Ac alpha-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer.
    J Nucl Med. 2025 Jun 5:jnumed.125.269601. doi: 10.2967/jnumed.125.269601.
    PubMed     Abstract available
    
    
    
21. MANSUR A, McConathy JE, Stringer-Reasor E, Rocque G, et al
    Quantitative [(89)Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI.
    J Nucl Med. 2025 Jun 5:jnumed.124.268931. doi: 10.2967/jnumed.124.268931.
    PubMed     Abstract available
    
    
    May 2025
22. LYNCH SE, Crawford C, Hunt AL, Sligh LL, et al
    Granzyme B PET Imaging Predicts Response to Immunotherapy in a Diet-Induced Obesity Model of Breast Cancer.
    J Nucl Med. 2025 May 29:jnumed.124.268938. doi: 10.2967/jnumed.124.268938.
    PubMed     Abstract available
    
    
    
23. YEH R, Pareja F, Shobeiri P, Ross D, et al
    Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis.
    J Nucl Med. 2025 May 8:jnumed.124.269227. doi: 10.2967/jnumed.124.269227.
    PubMed     Abstract available
    
    
    April 2025
24. HACHEY JS, Viray TD, Matasci M, Ravazza D, et al
    Targeting Extra Domain A of Fibronectin to Improve Noninvasive Detection of Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Apr 17:jnumed.124.268859. doi: 10.2967/jnumed.124.268859.
    PubMed     Abstract available
    
    
    March 2025
25. SABAHI Z, Nguyen A, Wong K, Li S, et al
    Diagnostic Potential of (68)Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease.
    J Nucl Med. 2025 Mar 27:jnumed.124.268896. doi: 10.2967/jnumed.124.268896.
    PubMed     Abstract available
    
    
    
26. PARIHAR AS, Vaz S, Sutcliffe S, Pant N, et al
    (18)F-Fluoroestradiol PET/CT for Predicting Benefit from Endocrine Therapy in Patients with Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Metaanalysis.
    J Nucl Med. 2025 Mar 13:jnumed.124.269163. doi: 10.2967/jnumed.124.269163.
    PubMed     Abstract available
    
    
    February 2025
27. BABEKER H, Njotu FN, Pougoue Ketchemen J, Monzer A, et al
    (225)Ac/(89)Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4-Positive Triple-Negative Breast Cancer.
    J Nucl Med. 2025 Feb 20:jnumed.124.268387. doi: 10.2967/jnumed.124.268387.
    PubMed     Abstract available
    
    
    
28. SUN L, Sun Y, Zuo K, Fan L, et al
    Pilot Study of Nectin-4-Targeted PET Imaging Agent (68)Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human.
    J Nucl Med. 2025 Feb 13:jnumed.124.269024. doi: 10.2967/jnumed.124.269024.
    PubMed     Abstract available
    
    
    
29. SUN Y, Hao Z, Gao H, Yang G, et al
    [(99m)Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study.
    J Nucl Med. 2025 Feb 13:jnumed.124.268564. doi: 10.2967/jnumed.124.268564.
    PubMed     Abstract available
    
    
    January 2025
30. VAN GEEL JJL, Moustaquim J, Boers J, Elias SG, et al
    Intrapatient 16alpha-[(18)F]Fluoro-17beta-Estradiol PET Heterogeneity as a Prognostic Factor for Endocrine Therapy Response and Survival in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    J Nucl Med. 2025 Jan 23:jnumed.124.268984. doi: 10.2967/jnumed.124.268984.
    PubMed     Abstract available
    
    
    December 2024
31. WEEKS JK, Pantel AR, Gitto SB, Liu F, et al
    [(18)F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [(18)F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
    J Nucl Med. 2024 Dec 5:jnumed.124.267627. doi: 10.2967/jnumed.124.267627.
    PubMed     Abstract available
    
    
    October 2024
32. YOUNG AJ, Pantel AR, Kiani M, Doot RK, et al
    Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted (18)F-Fluorthanatrace PET in Breast Cancer.
    J Nucl Med. 2024 Oct 30:jnumed.124.268254. doi: 10.2967/jnumed.124.268254.
    PubMed     Abstract available
    
    
    
33. JANNUSCH K, Umutlu L, Kirchner J, Bruckmann NM, et al
    Impact of (18)F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial.
    J Nucl Med. 2024 Oct 10:jnumed.124.268065. doi: 10.2967/jnumed.124.268065.
    PubMed     Abstract available
    
    
    
34. RYU J, Hyung J, Han S, Jeong JH, et al
    Impact of (18)F-FES PET/CT on Clinical Decisions in the Management of Recurrent or Metastatic Breast Cancer.
    J Nucl Med. 2024 Oct 3:jnumed.124.267913. doi: 10.2967/jnumed.124.267913.
    PubMed     Abstract available
    
    
    September 2024
35. EISSES B, van Geel JJL, Brouwers AH, Bensch F, et al
    Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.
    J Nucl Med. 2024 Sep 5:jnumed.124.267636. doi: 10.2967/jnumed.124.267636.
    PubMed     Abstract available
    
    
    August 2024
36. MWANIA MM, Gitau SN, Shah J, Makhdomi K, et al
    Association Between CA 15-3 and (18)F-FDG PET/CT Findings in Recurrent Breast Cancer Patients at a Tertiary Referral Hospital in Kenya.
    J Nucl Med. 2024 Aug 29:jnumed.124.267851. doi: 10.2967/jnumed.124.267851.
    PubMed     Abstract available
    
    
    June 2024
37. PHAM TT, Chenoweth A, Patel N, Banu A, et al
    In Vivo PET Imaging of (89)Zr-Labeled Natural Killer Cells and the Modulating Effects of a Therapeutic Antibody.
    J Nucl Med. 2024 Jun 6:jnumed.124.267876. doi: 10.2967/jnumed.124.267876.
    PubMed     Abstract available
    
    
    April 2024
38. ZHOU W, Halder S, Herwald S, Ghijsen M, et al
    Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas.
    J Nucl Med. 2024 Apr 25:jnumed.123.266659. doi: 10.2967/jnumed.123.266659.
    PubMed     Abstract available
    
    
    
39. MOSER R, Pfeiffer S, Cala L, Klein E, et al
    Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
    PubMed     Abstract available
    
    
    
40. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
    Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
    J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
    PubMed     Abstract available
    
    
    March 2024
41. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
    Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
    J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
    PubMed     Abstract available
    
    
    
42. SAHIN E, Kus T, Aytekin A, Uzun E, et al
    (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
    J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
    PubMed     Abstract available
    
    
    February 2024
43. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum